Brachytherapy for clinically localized prostate cancer: Results at 7- and 8-year follow-up
✍ Scribed by Haakon Ragde; John C. Blasko; Peter D. Grimm; Gerald M. Kenny; John Sylvester; David C. Hoak; William Cavanagh; Kent Landin
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 100 KB
- Volume
- 13
- Category
- Article
- ISSN
- 8756-0437
No coin nor oath required. For personal study only.
✦ Synopsis
In recent years, there has been a resurgence of interest in interstitial radiation as a cost-effective and efficient method of treating organ-confined prostate cancer. We describe our 7- and 8-year results with transperineal Iodine-125 and Palladium-103 implantation. A total of 551 consecutive patients were treated. Of these, 320/551 (58%) received implant alone (Group I), and 231/551 (42%)--considered higher risk patients--were also treated with a modest dose (45 Gy) of external beam irradiation (Group II). The median follow-up for Group I was 55 months, and for Group II, 60 months. At 7 years, the actuarial freedom from biochemical failure (prostate-specific antigen (PSA) < or = 1.0 ng/mL) was 80% in Group I patients, and, at 8 years, 65% in Group II patients. Morbidity was minimal if patients had not undergone prior transurethral prostate resections. The results indicate that interstitial radiation is a valid treatment for clinically localized prostate cancer.